Charles D. Loftin

Affiliations: 
University of Kentucky, Lexington, KY 
Area:
Pharmacology, Pharmacy, Molecular Biology
Google:
"Charles Loftin"
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Oestreich JH, Steinhubl SR, Ferraris SP, et al. (2014) Effect of genetic variation in P2Y12 on TRAP-stimulated platelet response in healthy subjects. Journal of Thrombosis and Thrombolysis. 38: 372-9
Trivedi DB, Loftin CD, Clark J, et al. (2013) β-Arrestin-2 deficiency attenuates abdominal aortic aneurysm formation in mice. Circulation Research. 112: 1219-29
Ghoshal S, Loftin CD. (2012) Cyclooxygenase-2 inhibition attenuates abdominal aortic aneurysm progression in hyperlipidemic mice. Plos One. 7: e44369
Mukherjee K, Gitlin JM, Loftin CD. (2012) Effectiveness of cyclooxygenase-2 inhibition in limiting abdominal aortic aneurysm progression in mice correlates with a differentiated smooth muscle cell phenotype. Journal of Cardiovascular Pharmacology. 60: 520-9
Banks SL, Paudel KS, Brogden NK, et al. (2011) Diclofenac enables prolonged delivery of naltrexone through microneedle-treated skin. Pharmaceutical Research. 28: 1211-9
Ghoshal S, Trivedi DB, Graf GA, et al. (2011) Cyclooxygenase-2 deficiency attenuates adipose tissue differentiation and inflammation in mice. The Journal of Biological Chemistry. 286: 889-98
Long S, Theiss KL, Mattei A, et al. (2010) Solid-state properties of the cyclooxygenase-1-selective inhibitor, SC-560. Aaps Pharmscitech. 11: 485-8
Long S, Theiss KL, Li T, et al. (2009) Cyclo-oxygenase-1-selective inhibitor SC-560. Acta Crystallographica. Section E, Structure Reports Online. 65: o360
Kelso ML, Scheff SW, Pauly JR, et al. (2009) Effects of genetic deficiency of cyclooxygenase-1 or cyclooxygenase-2 on functional and histological outcomes following traumatic brain injury in mice. Bmc Neuroscience. 10: 108
Gitlin JM, Loftin CD. (2009) Cyclooxygenase-2 inhibition increases lipopolysaccharide-induced atherosclerosis in mice. Cardiovascular Research. 81: 400-7
See more...